CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

paromomycin

Trade name: humatin

Small moleculeapproved

Approved

Mar 24, 1969

Paromomycin is a broad spectrum aminoglycoside antibiotic produced by by Streptomyces rimosus var. paromomycinus and used to treat intestinal infections such as cryptosporidiosis and amoebiasis, and other diseases such as leishmaniasis. Paromomycin is also used for the management of hepatic coma as adjunctive therapy. Paromomycin inhibits protein synthesis by binding to bacterial or protozoal 16S ribosomal RNA which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death. Gastrointestinal side effects include nausea, vomiting, diarrhea, and abdominal discomfort. — NCATS

Clinical trial activity

34 trials · 41 clinical orgs · 4 marketing orgs

Phase 1
1
Phase 2
21
Phase 3
11
Phase 4
1

Earliest trial started Nov 1, 1994 (NCT00004444)

Timeline

1960s

  1. Mar 24, 1969

    Parke-Davis — Earliest FDA Approval

  2. Mar 24, 1969

    Parke-Davis — Marketing Organization

  3. Mar 24, 1969

    Parke-Davis — NDA Organization

1980s

  1. Jan 5, 1981

    Pfizer — Marketing Organization

1990s

  1. Jun 30, 1997

    Sun Pharmaceuticals — Marketing Organization

  2. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Dec 14, 2007

    Heritage Pharma — Marketing Organization

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedMar 24, 1969

Chemistry & pharmacology

Loading structure…

SMILES

NC[C@@H]1O[C@H](O[C@H]2[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)O[C@@H]2CO)[C@H](N)[C@@H](O)[C@@H]1O
Mol. weight
615.63 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • (1r,2r,3s,4r,6s)-4,6-diamino-2-{[3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside
  • (1r,2r,3s,4r,6s)-4,6-diamino-2-{[3-o-(2,6-diamino-2,6-dideoxy-beta-l-idopyranosyl)-beta-d-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside
  • ameparomo
  • ameparomo
  • ameparomo
  • ameparomo
  • ameparomo
  • ameparomo
  • aminosidin
  • aminosidin
  • aminosidin
  • aminosidine
  • aminosidine
  • aminosidine
  • aminosidine
  • aminosidine sulfate
  • aminosidine sulfate
  • catenulin
  • catenulin
  • catenulin
  • crestomycin
  • crestomycin
  • crestomycin
  • crestomycin sulfate
  • crestomycin sulfate
  • estomycin
  • estomycin
  • estomycin sulfate
  • estomycin sulfate
  • gabbroral
  • gabbroral
  • gentamicin sulfate mixture with paromomycin sulfate
  • humatin
  • humatin
  • humatin
  • hydroxymycin
  • hydroxymycin
  • liposomal paromomycin
  • monomycin
  • monomycin
  • monomycin a
  • monomycin a
  • neomycin e
  • neomycin e
  • neosporin
  • neosporin
  • neosporin
  • paramomycin
  • paramomycin
  • parmomycin
  • paromomicina
  • paromomicina
  • paromomycin
  • paromomycin
  • paromomycin
  • paromomycin
  • paromomycin
  • paromomycin
  • paromomycin
  • paromomycin
  • paromomycine
  • paromomycine
  • paromomycine
  • paromomycin i
  • paromomycin i
  • paromomycin sulfate
  • paromomycin sulfate
  • paromomycin sulfate
  • paromomycin sulfate
  • paromomycin sulfate
  • paromomycin sulphate
  • paromomycin sulphate
  • paromomycin sulphate
  • paromomycinum
  • paromomycinum
  • paromycin
  • paucimycin
  • paucimycin
  • paucimycin
  • paucimycinum
  • paucimycinum
  • polysporin
  • polysporin
  • polysporin
  • wr279,396
  • zygomycin a1
  • zygomycin a1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05957978Phase 2Jan 31, 2024Drugs for Neglected Diseases Initiative, Novartis, University of Gondar
NCT06907498N/AJan 22, 2024Tel Aviv University
NCT03829917Phase 2/Phase 3 (Phase 3)Feb 28, 2019Fundacion Nacional de Dermatologia, Government of Bolivia, Hospital Dermatológico de Jorochito, The Alfred Berman Foundation for Medical Research
NCT03399955Phase 2May 9, 2018Drugs for Neglected Diseases Initiative
NCT03129646Phase 3Aug 1, 2017Drugs for Neglected Diseases Initiative, Institute of Endemic Diseases, Sudan, Kenya Medical Research Institute, Makerere University, Netherlands Cancer Institute, University of Gondar, University of Khartoum
NCT03096457Phase 2/Phase 3 (Phase 3)Apr 15, 2017Fundacion Nacional de Dermatologia
NCT02730117N/AMar 1, 2016Chulalongkorn University
NCT01140191Phase 2Sep 1, 2013United States Army
NCT01988909Phase 2Sep 1, 2013United States Army, University of Paris
NCT01790659Phase 3May 1, 2013Instituto Conmemorativo Gorgas de Estudios de la Salud, United States Army
NCT01780909N/AFeb 1, 2013Katholieke Universiteit Leuven
NCT01641796N/AJun 18, 2012Uniformed Services University of the Health Sciences, United States Army
NCT01672593N/AMay 1, 2012Jinlin University
NCT01494350Phase 2Dec 1, 2011Institut Pasteur, United States Army
NCT02366884Phase 2Jul 1, 2011Dr. Frank Arguello Cancer Clinic, Instituto de Ciencia y Medicina Genomica
NCT01050777Early Phase 1 (Phase 1)Mar 1, 2011Isfahan University, Mashhad University of Medical Sciences, University of Tehran
NCT01328457N/AJan 1, 2011GVK Biosciences Pvt. Ltd, International Center for Diarrheal Disease Research, PATH, Shaheed Suhrawardy Medical College
NCT01122771Phase 3May 1, 2010Drugs for Neglected Diseases Initiative, International Center for Diarrheal Disease Research, Shaheed Suhrawardy Medical College
NCT01083576Phase 2Mar 1, 2010Instituto Conmemorativo Gorgas de Estudios de la Salud, United States Army
NCT01032382Phase 2Jan 1, 2010Cayetano Heredia University, United States Army
Showing 20 of 34 trials
Page 1 / 2

Organizations

Research & Development (41)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
United States ArmyGovernment121132003
Drugs for Neglected Diseases InitiativeAcademic/Hospital7622004
Institut PasteurAcademic/Hospital5032003
PATHAcademic/Hospital3332003
Rajendra Memorial Research Institute of Medical SciencesAcademic/Hospital3022003
Banaras Hindu UniversityAcademic/Hospital2212007
Fundacion Nacional de DermatologiaAcademic/Hospital2212017
Instituto Conmemorativo Gorgas de Estudios de la SaludAcademic/Hospital2022010
International Center for Diarrheal Disease ResearchAcademic/Hospital2022010
Kala-azar Medical Research CentreAcademic/Hospital2022003
National Institute of Allergy and Infectious Diseases (NIAID)Government2221999
Shaheed Suhrawardy Medical CollegeAcademic/Hospital2022010
Uniformed Services University of the Health SciencesGovernment2022004
University of GondarAcademic/Hospital2022017
Cayetano Heredia UniversityAcademic/Hospital1012010
Chulalongkorn UniversityAcademic/Hospital1112016
Dr. A.K. Aditya ClinicAcademic/Hospital1012007
Dr. Frank Arguello Cancer ClinicAcademic/Hospital1112011
Food and Drug AdministrationGovernment1111994
Genetics InstituteFor profit1012000
41 organizations
Page 1 / 3

Marketing (7)

OrganizationOrg typeRelationshipDate
Heritage PharmaFor profitMKTGDec 14, 2007
Heritage PharmaFor profitSYNDec 14, 2007
Heritage PharmaFor profitSYNDec 14, 2007
Parke-DavisFor profitMKTGMar 24, 1969
Parke-DavisFor profitNDAMar 24, 1969
PfizerFor profitMKTGJan 5, 1981
Sun PharmaceuticalsFor profitMKTGJun 30, 1997